The miR-140-5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma
- PMID: 32596959
- DOI: 10.1096/fj.202000088RR
The miR-140-5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma
Erratum in
-
Erratum to "The miR-140-5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma".FASEB J. 2024 Mar 31;38(6):e23580. doi: 10.1096/fj.202400584. FASEB J. 2024. PMID: 38517740 No abstract available.
Abstract
Although renal cell carcinoma (RCC) is a common malignant urological cancer, its pathogenesis remains unclear. Previous studies have indicated that miR-140-5p acts as a tumor suppressor in various tumors, including bladder cancer, hepatocellular carcinoma, and gastric cancer, but its biological function in RCC remains unknown. In the present study, we found that miR-140-5p was upregulated in RCC tissues, whereas Krüppel-like factor 9 (KLF9) was downregulated and correlated inversely with miR-140-5p in RCC tissues. miR-140-5p promoted the proliferation, migration, and invasion of RCC cells in vitro, and knockdown of miR-140-5p significantly suppressed tumor growth and lung metastasis in nude mouse model of RCC. We also found that miR-140-5p significantly suppressed the expression of KLF9 by binding to the 3'-UTR of KLF9 mRNA and that KLF9, as a transcription factor, upregulates KCNQ1 (also called Kv 7.1 and Kv LQT1) expression by binding to the site (-841/-827) in the KCNQ1 promoter region in RCC cells. Moreover, forced expression of KCNQ1 decreased the growth and metastasis of RCC cells. These results suggest that the miR-140-5p/KLF9/KCNQ1 axis functions as a key signaling pathway in RCC progression and metastasis and represents a potential target of RCC therapies.
Keywords: KCNQ1; KLF9; miR-140-5p; proliferation/invasion/metastasis; renal cell carcinoma.
© 2020 Federation of American Societies for Experimental Biology.
Comment in
-
Uro-Science.J Urol. 2021 Apr;205(4):1228-1229. doi: 10.1097/JU.0000000000001605. Epub 2021 Jan 21. J Urol. 2021. PMID: 33472375 No abstract available.
References
REFERENCES
-
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
-
- Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67:507-524.
-
- Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109:1763-1768.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical